期刊
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
卷 19, 期 5, 页码 705-715出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2005.05.007
关键词
carcinoid; neuroendocrine; endocrine; tumour; syndrome; octreotide; interferon; somatostatin; chemotherapy; imaging; octreoscan; CT; MRI; flushing; pellagra; diarrhoea; abdominal pain; heart; tricuspid valve; pulmonary valve; fibrosis
(Neuro-)endocrine tumours of the gastrointestinal tract are also called 'carcinoids'. (Neuro-) endocrine midgut tumours can be categorized according to their clinical behaviour. Most tumours are non-functioning. Functioning tumours are responsible for the carcinoid syndrome. The carcinoid syndrome is almost uniquely associated with midgut carcinoids. Symptoms of the carcinoid syndrome are caused by an excess of biogenic amines, peptides and other factors in the circulation. The typical symptoms of the carcinoid syndrome are diarrhoea, flushing, and carcinoid heart disease. Carcinoid heart disease involves the tricuspid and pulmonary valves and the endocardium. Serum chromogranin A and urinary excretion of 5-hydroxy-indoleacetic acid (5-HIAA) are biochemical markers. Carcinoid tumours express large numbers of high-affinity somatostatin receptors. These can bind the currently available octapepticle somatostatin analogues. In inoperable patients, biotherapy with somatostatin analogues and interferon-a is the treatment of choice. Somatostatin analogues and interferon-alpha significantly improve symptoms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据